A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and an 8-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.

NCT Number	NCT07432958
Lead Sponsor	Appello Pharmaceuticals, Inc.
Conditions	Parkinson Disease
Enrollment	150 participants
Start Date	2026-02-25
Primary Completion	2027-09-03 (estimated)
Study Completion	2028-01-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-11